FNA
Get informed when a big investor buys or sells
+ Follow| Market cap | $1.10 Billion |
|---|---|
| Enterprise Value | $1.18 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.66 |
| Beta | 1.47 |
| Outstanding Shares | 83,311,245 |
| P/E Ratio | -19.96 |
|---|---|
| PEG | 46.26 |
| Price to Sales | 4.36 |
| Price to Book Ratio | 13.09 |
| Enterprise Value to Revenue | 4.59 |
| Enterprise Value to EBIT | -29.97 |
| Enterprise Value to Net Income | -23 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.85 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
No data
This powerful committee controls taxation, trade, and entitlement spending (Medicare, Medicaid). Its decisions on corporate tax policy, as well as Medicare/Medicaid reimbursement rates and coverage, directly impact the profitability and market access of medical device manufacturers like Paragon 28.
This committee allocates discretionary federal spending. Its subcommittees make precise funding decisions for federal healthcare programs, medical research (e.g., NIH), and VA purchasing, directly impacting potential revenue streams and R&D opportunities for medical device companies.
This committee regulates the FDA, which is the primary regulatory body for medical devices. Its oversight of drug and device approval processes, medical research funding (NIH), and healthcare policy directly impacts Paragon 28's core business, product development, and market access.
This committee oversees intellectual property law (patents are critical for medical devices) and antitrust enforcement. Its decisions on mergers, competition, and IP protection directly impact the legal and competitive landscape for medical device companies like Paragon 28.
The Department of Veterans Affairs (VA) is a major healthcare provider and purchaser of medical devices. This committee's funding decisions and oversight directly impact government healthcare contractors and medical device manufacturers like Paragon 28.